{"text_format":"3","workbook":"xlsx","n_sheets":1,"sheets":["Sheet1"],"read":"whole","date_system":"1900"}

{"sheet":"Sheet1","index":0,"n_rows":31,"n_cols":2,"rows_kept":31,"merged":[[30,0,32,1]]}
["Table 1. Baseline demographic and clinicopathological characteristics of non-M3 AML patients"]
["Characteristics","Total (n=360)"]
["Age, yr, median (IQR)","48(33-59)"]
["Sex"]
["  Male","198(55%)"]
["  Female","162(45%)"]
["WBC count, ×109/L, median (IQR)","18.25(5.54-54.33)"]
["Hemoglobin, g/L, median (IQR)","82.50(66.00-103.25)"]
["Platelet, ×109/L, median (IQR)","40.50(19.75-86.25)"]
["Blasts in PB, %, median (IQR)","54.00(21.50-78.00)"]
["Blasts in BM, %, median (IQR)","66.00(45.80-83.28)"]
["Albumin, g/L, median (IQR)","35.95(32.75-39.52)"]
["FAB subtypes"]
["  M0","0(0.00%)"]
["  M1","1(0.28%)"]
["  M2","53(14.72%)"]
["  M4","147(40.83%)"]
["  M5","132(36.67%)"]
["  M6","8(2.22%)"]
["  M7","1(0.28%)"]
["  Unclassified","18(5.00%)"]
["Cyto/molecular genetic risk group"]
["  Favorable","70(19.44%)"]
["  Intermediate","195(54.17%)"]
["  Unfavorable","83(23.06%)"]
["  Missing","12(3.33%)"]
["allo-HSCT"]
["  Yes","77(21.39%)"]
["  No","283(78.61%)"]
[]
["Abbreviations: WBC, white blood cell; PB, peripheral blood; BM, bone marrow; FAB, French-American-British,  allo-HSCT, allogeneic hematopoietic stem cell transplantation."]